At a glance
- Originator Seikagaku Corporation
- Developer Nonindustrial source; Seikagaku Corporation
- Class Antineoplastics
- Mechanism of Action Protein kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jul 2001 This compound is still in active development in the USA
- 09 Jul 1998 Profile reviewed
- 09 May 1995 Preclinical development for Cancer in Japan (Unknown route)